PRELID3BP7

Across TCGA pan-cancer cohorts, PRELID3BP7 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PRELID3BP7’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRELID3BP7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRELID3BP7 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

KIRC and LUSC are the cancer types where PRELID3BP7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRELID3BP7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.041	.014	3	view →
LUSC	All	All	−0.057	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PRELID3BP7–KIRC

Open the KIRC breakdown →